All Nanexa AB articles
-
NewsNovo secures €1.17bn long-acting injectable deal with Nanexa
Licensing agreement focuses on a delivery technology that provides sustained-release injectable peptides and offers potential to reduce treatment burden in obesity and type 2 diabetes.
-
NewsNanexa collaboration to enhance Moderna’s mRNA drug delivery
Moderna’s $500 million deal with Nanexa will focus on improving long-acting injectable drug delivery, potentially improving mRNA medicines.